ANA Hails Court Ruling Blocking HHS Price Disclosure Rule

FOR IMMEDIATE RELEASE

ANA HAILS COURT RULING BLOCKING HHS PRICE DISCLOSURE RULE

WASHINGTON (JULY 9, 2019) – ANA strongly supports yesterday’s ruling of the United States District Court for the District of Columbia striking down the proposed Health and Human Services (HHS) rule to mandate price disclosures in most prescription drug ads. ANA joined with Merck, Amgen, and Eli Lilly in suing in opposition to the rule. The court found that Congress had not provided HHS the authority to impose the rule. 

Dan Jaffe, ANA’s Group Executive Vice President for Government Relations, stated, “This decision was an important victory for the public and the advertising community. The rule required price disclosures that would have been highly inflated, misleading and inaccurate for a vast number of consumers.”

Jaffe emphasized that, “The rule clearly violates the First Amendment and would not further the goal of lowering prescription drug prices, while creating broad adverse precedents extending far beyond the prescription drug area.”

Jaffe concluded, “ANA will continue to vigorously uphold the vital First Amendment rights of the advertising community.”

To learn more about ANA and our efforts to defend free speech, visit www.ana.net/advocacy.   

ABOUT THE ANA:

The Association of National Advertisers (ANA) is the definitive voice of the marketing industry. Since 1910, we have set and advanced the agenda for marketing transformation, connecting over 1,600 member companies to an influential global network, insights and resources that drive growth. Our members represent 20,000 brands and $400 billion in annual marketing investment. Through industry-leading research, the CMO Growth Council, and our proprietary Growth Agenda and Practices, the ANA empowers marketers to shape the future of marketing and create lasting impact for their organizations and the industry.

MEDIA CONTACT:
Dan Jaffe, ANA Group EVP Government Relations
Office: 202.296.2359
Mobile: 646.369.4886
Email: [email protected]